Seelos Therapeutics, Inc. SEELQ

SEELQ Company Overview

Seelos Therapeutics, Inc. (OTC: SEELQ) was a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders and rare diseases. The company operated within the biotechnology and pharmaceutical industries, with a primary emphasis on neurological, psychiatric, and neurodegenerative conditions that had limited approved treatment options. Its pipeline historically included drug candidates targeting disorders such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, major depressive disorder, and acute suicidal ideation and behavior. Revenue generation was limited because the company remained largely in the clinical development stage and had not commercialized approved products according to publicly available filings.

The company evolved through a series of mergers, licensing transactions, and pipeline acquisitions after being formed in 2017 through the merger of Seelos Therapeutics and Apricus Biosciences. Seelos sought to differentiate itself by focusing on repurposed or reformulated compounds with potential CNS applications and orphan-drug opportunities. Public disclosures and market reports indicate the company relied heavily on capital raises, strategic licensing arrangements, and research collaborations to fund development activities. As of recent public records associated with the OTC ticker SEELQ, the company appeared to be undergoing financial distress and restructuring proceedings. Data regarding ongoing operations after its OTC designation is limited and partially inconclusive based on available public sources.